Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Combinatorial Antitumor Activity of Oxaliplatin with Epigenetic Modifying Agents, 5-Aza-CdR and FK228, in Human Gastric Cancer Cells

  • Park, Jong Kook (Department of Biomedical Science and Research Institute for Bioscience & Biotechnology, Hallym University) ;
  • Seo, Jung Seon (Department of Biomedicine & Health Science, Graduate School, The Catholic University of Korea) ;
  • Lee, Suk Kyeong (Department of Biomedicine & Health Science, Graduate School, The Catholic University of Korea) ;
  • Chan, Kenneth K (Comprehensive Cancer Center, The Ohio State University) ;
  • Kuh, Hyo-Jeong (Department of Biomedicine & Health Science, Graduate School, The Catholic University of Korea)
  • Received : 2018.04.13
  • Accepted : 2018.07.31
  • Published : 2018.11.01
Download PDF
⟨ Previous Next ⟩

Abstract

Epigenetic silencing is considered to be a major mechanism for loss of activity in tumor suppressors. Reversal of epigenetic silencing by using inhibitors of DNA methyltransferase (DNMT) or histone deacetylases (HDACs) such as 5-Aza-CdR and FK228 has shown to enhance cytotoxic activities of several anticancer agents. This study aims to assess the combinatorial effects of genesilencing reversal agents (5-Aza-CdR and FK228) and oxaliplatin in gastric cancer cells, i.e., Epstein-Barr virus (EBV)-negative SNU-638 and EBV-positive SNU-719 cells. The doublet combinatorial treatment of 5-Aza-CdR and FK228 exhibited synergistic effects in both cell lines, and this was further corroborated by Zta expression induction in SNU-719 cells. Three drug combinations as 5-Aza-CdR/FK228 followed by oxaliplatin, however, resulted in antagonistic effects in both cell lines. Simultaneous treatment with FK228 and oxaliplatin induced synergistic and additive effects in SNU-638 and SNU-719 cells, respectively. Three drug combinations as 5-Aza-CdR prior to FK228/oxaliplatin, however, again resulted in antagonistic effects in both cell lines. This work demonstrated that efficacy of doublet synergistic combination using DNMT or HDACs inhibitors can be compromised by adding the third drug in pre- or post-treatment approach in gastric cancer cells. This implies that the development of clinical trial protocols for triplet combinations using gene-silencing reversal agents should be carefully evaluated in light of their potential antagonistic effects.

Keywords

References

  1. Ateeq, B., Unterberger, A., Szyf, M. and Rabbani, S. A. (2008) Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 10, 266-278. https://doi.org/10.1593/neo.07947
  2. Banerjee, A. S., Pal, A. D. and Banerjee, S. (2013) Epstein-Barr virusencoded small non-coding RNAs induce cancer cell chemoresistance and migration. Virology 443, 294-305. https://doi.org/10.1016/j.virol.2013.05.020
  3. Bang, Y. J., Kim, Y. W., Yang, H. K., Chung, H. C., Park, Y. K., Lee, K. H., Lee, K. W., Kim, Y. H., Noh, S. I., Cho, J. Y., Mok, Y. J., Kim, Y. H., Ji, J., Yeh, T. S., Button, P., Sirzen, F. and Noh, S. H. (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379, 315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
  4. Baylin, S. B. and Ohm, J. E. (2006) Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6, 107-116. https://doi.org/10.1038/nrc1799
  5. Bittoni, A., Del Prete, M., Scartozzi, M., Pistelli, M., Giampieri, R., Faloppi, L., Bianconi, M. and Cascinu, S. (2015) Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. Springerplus 4, 743. https://doi.org/10.1186/s40064-015-1545-y
  6. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G. and Baylin, S. B. (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21, 103-107. https://doi.org/10.1038/5047
  7. Cayrol, C. and Flemington, E. (1996) G0/G1 growth arrest mediated by a region encompassing the basic leucine zipper (bZIP) domain of the Epstein-Barr virus transactivator Zta. J. Biol. Chem. 271, 31799-31802. https://doi.org/10.1074/jbc.271.50.31799
  8. Chao, Y., Yeh, K. H., Chang, C. J., Chen, L. T., Chao, T. Y., Wu, M. F., Chang, C. S., Chang, J. Y., Chung, C. Y., Kao, W. Y., Hsieh, R. K. and Cheng, A. L. (2004) Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br. J. Cancer 91, 453-458. https://doi.org/10.1038/sj.bjc.6601985
  9. Choi, S. H., Byun, H. M., Kwan, J. M., Issa, J. P. and Yang, A. S. (2007) Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br. J. Haematol. 138, 616-623. https://doi.org/10.1111/j.1365-2141.2007.06707.x
  10. Chou, T. C. and Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55. https://doi.org/10.1016/0065-2571(84)90007-4
  11. Christman, J. K., Mendelsohn, N., Herzog, D. and Schneiderman, N. (1983) Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res. 43, 763-769.
  12. Chung, W. H., Sung, B. H., Kim, S. S., Rhim, H. and Kuh, H. J. (2009) Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. Int. J. Oncol. 34, 1669-1679.
  13. Cooper, S. J., von Roemeling, C. A., Kang, K. H., Marlow, L. A., Grebe, S. K., Menefee, M. E., Tun, H. W., Colon-Otero, G., Perez, E. A. and Copland, J. A. (2012) Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers. Mol. Cancer Ther. 11, 2105-2115. https://doi.org/10.1158/1535-7163.MCT-11-0873
  14. Eriguchi, M., Nonaka, Y., Yanagie, H., Yoshizaki, I., Takeda, Y. and Sekiguchi, M. (2003) A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines. Biomed. Pharmacother. 57, 412-415. https://doi.org/10.1016/S0753-3322(03)00027-1
  15. Feng, W. H., Westphal, E., Mauser, A., Raab-Traub, N., Gulley, M. L., Busson, P. and Kenney, S. C. (2002) Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J. Virol. 76, 10951-10959. https://doi.org/10.1128/JVI.76.21.10951-10959.2002
  16. Fukayama, M. (2010) Epstein-Barr virus and gastric carcinoma. Pathol. Int. 60, 337-350. https://doi.org/10.1111/j.1440-1827.2010.02533.x
  17. Fuks, F. (2005) DNA methylation and histone modifications: teaming up to silence genes. Curr. Opin. Genet. Dev. 15, 490-495. https://doi.org/10.1016/j.gde.2005.08.002
  18. Glaser, K. B. (2006) Defining the role of gene regulation in resistance to HDAC inhibitors--mechanisms beyond P-glycoprotein. Leuk. Res. 30, 651-652. https://doi.org/10.1016/j.leukres.2005.10.016
  19. Gomyo, Y., Sasaki, J., Branch, C., Roth, J. A. and Mukhopadhyay, T. (2004) 5-aza-2'-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene 23, 6779-6787. https://doi.org/10.1038/sj.onc.1207381
  20. Gu, J., Yamamoto, H., Lu, X., Ngan, C. Y., Tsujino, T., Konishi, K., Takemasa, I., Ikeda, M., Nagata, H., Hashimoto, S., Matsuzaki, T., Sekimoto, M., Takagi, A. and Monden, M. (2006) Low-dose oxaliplatin enhances the antitumor efficacy of paclitaxel in human gastric cancer cell lines. Digestion 74, 19-27. https://doi.org/10.1159/000095826
  21. Hassan, H. E., Keita, J. A., Narayan, L., Brady, S. M., Frederick, R., Carlson, S., Glass, K. C., Natesan, S., Buttolph, T. and Fandy, T. E. (2016) The combination of dimethoxycurcumin with DNA methylation inhibitor enhances gene re-expression of promoter-methylated genes and antagonizes their cytotoxic effect. Epigenetics [Epub ahead of print].
  22. Hui, K. F., Ho, D. N., Tsang, C. M., Middeldorp, J. M., Tsao, G. S. and Chiang, A. K. (2012) Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. Int. J. Cancer 131, 1930-1940. https://doi.org/10.1002/ijc.27439
  23. Ierano, C., Chakraborty, A. R., Nicolae, A., Bahr, J. C., Zhan, Z., Pittaluga, S., Bates, S. E. and Robey, R. W. (2013) Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors. Cell Cycle 12, 2829-2838. https://doi.org/10.4161/cc.25914
  24. Johnson, K. R., Wang, L., Miller, M. C., 3rd, Willingham, M. C. and Fan, W. (1997) 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin. Cancer Res. 3, 1739-1745.
  25. Jones, P. A. and Baylin, S. B. (2007) The epigenomics of cancer. Cell 128, 683-692. https://doi.org/10.1016/j.cell.2007.01.029
  26. Kalac, M., Scotto, L., Marchi, E., Amengual, J., Seshan, V. E., Bhagat, G., Ulahannan, N., Leshchenko, V. V., Temkin, A. M., Parekh, S., Tycko, B. and O'Connor, O. A. (2011) HDAC inhibitors and decitabine are highly synergistic and associated with unique geneexpression and epigenetic profiles in models of DLBCL. Blood 118, 5506-5516. https://doi.org/10.1182/blood-2011-02-336891
  27. Kano, Y., Akutsu, M., Tsunoda, S., Izumi, T., Kobayashi, H., Mano, H. and Furukawa, Y. (2007) Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest. New Drugs 25, 31-40.
  28. Kanzaki, M., Kakinuma, H., Kumazawa, T., Inoue, T., Saito, M., Narita, S., Yuasa, T., Tsuchiya, N. and Habuchi, T. (2007) Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. Oncol. Rep. 17, 761-767.
  29. Karam, J. A., Fan, J., Stanfield, J., Richer, E., Benaim, E. A., Frenkel, E., Antich, P., Sagalowsky, A. I., Mason, R. P. and Hsieh, J. T. (2007) The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int. J. Cancer 120, 1795-1802. https://doi.org/10.1002/ijc.22405
  30. Kim, H., Choi, H. and Lee, S. K. (2015) Epstein-Barr virus miRBART20-5p regulates cell proliferation and apoptosis by targeting BAD. Cancer Lett. 356, 733-742. https://doi.org/10.1016/j.canlet.2014.10.023
  31. Kuendgen, A. and Lubbert, M. (2008) Current status of epigenetic treatment in myelodysplastic syndromes. Ann. Hematol. 87, 601-611. https://doi.org/10.1007/s00277-008-0477-9
  32. Laterza, M. M., Pompella, L., Petrillo, A., Tirino, G., Pappalardo, A., Orditura, M., Troiani, T., Ciardiello, F., Di Martino, N. and De Vita, F. (2017) Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. Med. Oncol. 34, 186. https://doi.org/10.1007/s12032-017-1046-7
  33. Lavelle, D., DeSimone, J., Hankewych, M., Kousnetzova, T. and Chen, Y. H. (2003) Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk. Res. 27, 999-1007. https://doi.org/10.1016/S0145-2126(03)00068-7
  34. Leao, M., Anderton, E., Wade, M., Meekings, K. and Allday, M. J. (2007) Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. J. Virol. 81, 248-260. https://doi.org/10.1128/JVI.01096-06
  35. Lee, J. H., Kim, S. H., Han, S. H., An, J. S., Lee, E. S. and Kim, Y. S. (2009) Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J. Gastroenterol. Hepatol. 24, 354-365. https://doi.org/10.1111/j.1440-1746.2009.05775.x
  36. Li, Y., Geng, P., Jiang, W., Wang, Y., Yao, J., Lin, X., Liu, J., Huang, L., Su, B. and Chen, H. (2014) Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells. Tumour Biol. 35, 4831-4839. https://doi.org/10.1007/s13277-014-1634-5
  37. Luo, H. Y., Wei, W., Shi, Y. X., Chen, X. Q., Li, Y. H., Wang, F., Qiu, M. Z., Li, F. H., Yan, S. L., Zeng, M. S., Huang, P. and Xu, R. H. (2010) Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. Oncol. Rep. 23, 1735-1745.
  38. Mizutani, H., Hiraku, Y., Tada-Oikawa, S., Murata, M., Ikemura, K., Iwamoto, T., Kagawa, Y., Okuda, M. and Kawanishi, S. (2010) Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide. Cancer Sci. 101, 2214-2219. https://doi.org/10.1111/j.1349-7006.2010.01645.x
  39. Momparler, R. L., Cote, S., Momparler, L. F. and Idaghdour, Y. (2017) Inhibition of DNA and histone methylation by 5-aza-2'-deoxycytidine (decitabine) and 3-Deazaneplanocin-A on antineoplastic action and gene expression in myeloid leukemic cells. Front. Oncol. 7, 19.
  40. Montagnani, F., Turrisi, G., Marinozzi, C., Aliberti, C. and Fiorentini, G. (2011) Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer 14, 50-55. https://doi.org/10.1007/s10120-011-0007-7
  41. Morabito, A., Carillio, G. and Longo, R. (2009) Systemic treatment of gastric cancer. Crit. Rev. Oncol. Hematol. 70, 216-234. https://doi.org/10.1016/j.critrevonc.2008.08.005
  42. Ni, X., Li, L. and Pan, G. (2015) HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (review). Oncol. Lett. 9, 515-521. https://doi.org/10.3892/ol.2014.2714
  43. Palii, S. S. and Robertson, K. D. (2007) Epigenetic control of tumor suppression. Crit. Rev. Eukaryot. Gene Expr. 17, 295-316. https://doi.org/10.1615/CritRevEukarGeneExpr.v17.i4.40
  44. Roell, K. R., Reif, D. M. and Motsinger-Reif, A. A. (2017) An introduction to terminology and methodology of chemical synergy-perspectives from across disciplines. Front. Pharmacol. 8, 158. https://doi.org/10.3389/fphar.2017.00158
  45. Shah, M. A. and Ajani, J. A. (2010) Gastric cancer--an enigmatic and heterogeneous disease. JAMA 303, 1753-1754. https://doi.org/10.1001/jama.2010.553
  46. Shang, D., Liu, Y., Matsui, Y., Ito, N., Nishiyama, H., Kamoto, T. and Ogawa, O. (2008) Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. Urology 71, 1220-1225. https://doi.org/10.1016/j.urology.2007.11.029
  47. Shi, M., Lou, B., Ji, J., Shi, H., Zhou, C., Yu, Y., Liu, B., Zhu, Z. and Zhang, J. (2013) Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells. Cancer Chemother. Pharmacol. 72, 35-44. https://doi.org/10.1007/s00280-013-2166-1
  48. Son, D. S., Wilson, A. J., Parl, A. K. and Khabele, D. (2010) The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Cancer Biol. Ther. 9, 928-935. https://doi.org/10.4161/cbt.9.11.11873
  49. Stanfield, B. A. and Luftig, M. A. (2017) Recent advances in understanding Epstein-Barr virus. F1000Res. 6, 386. https://doi.org/10.12688/f1000research.10591.1
  50. Sui, M., Dziadyk, J. M., Zhu, X. and Fan, W. (2004) Cell cycle-dependent antagonistic interactions between paclitaxel and gammaradiation in combination therapy. Clin. Cancer Res. 10, 4848-4857. https://doi.org/10.1158/1078-0432.CCR-03-0707
  51. Sun, W. J., Huang, H., He, B., Hu, D. H., Li, P. H., Yu, Y. J., Zhou, X. H., Lv, Z., Zhou, L., Hu, T. Y., Yao, Z. C., Lu, M. D., Shen, X. and Zheng, Z. Q. (2017) Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. Biochem. Pharmacol. 127, 90-100. https://doi.org/10.1016/j.bcp.2016.12.008
  52. Takayama, S., Wakasugi, T., Funahashi, H. and Takeyama, H. (2010) Strategies for gastric cancer in the modern era. World J. Gastrointest. Oncol. 2, 335-341. https://doi.org/10.4251/wjgo.v2.i9.335
  53. Tanaka, R., Ariyama, H., Qin, B., Shibata, Y., Takii, Y., Kusaba, H., Baba, E., Mitsugi, K., Harada, M. and Nakano, S. (2005) Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. Oncol. Rep. 14, 683-688.
  54. Tsai, H. C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F. V., Shin, J. J., Harbom, K. M., Beaty, R., Pappou, E., Harris, J., Yen, R. W., Ahuja, N., Brock, M. V., Stearns, V., Feller-Kopman, D., Yarmus, L. B., Lin, Y. C., Welm, A. L., Issa, J. P., Minn, I., Matsui, W., Jang, Y. Y., Sharkis, S. J., Baylin, S. B. and Zahnow, C. A. (2012) Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21, 430-446. https://doi.org/10.1016/j.ccr.2011.12.029
  55. Wang, L. X., Mei, Z. Y., Zhou, J. H., Yao, Y. S., Li, Y. H., Xu, Y. H., Li, J. X., Gao, X. N., Zhou, M. H., Jiang, M. M., Gao, L., Ding, Y., Lu, X. C., Shi, J. L., Luo, X. F., Wang, J., Wang, L. L., Qu, C., Bai, X. F. and Yu, L. (2013) Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS ONE 8, e62924. https://doi.org/10.1371/journal.pone.0062924
  56. Wildeman, M. A., Novalic, Z., Verkuijlen, S. A., Juwana, H., Huitema, A. D., Tan, I. B., Middeldorp, J. M., de Boer, J. P. and Greijer, A. E. (2012) Cytolytic virus activation therapy for Epstein-Barr virusdriven tumors. Clin. Cancer Res. 18, 5061-5070. https://doi.org/10.1158/1078-0432.CCR-12-0574
  57. Wilson, A. J., Lalani, A. S., Wass, E., Saskowski, J. and Khabele, D. (2012) Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. Gynecol. Oncol. 127, 579-586. https://doi.org/10.1016/j.ygyno.2012.09.016
  58. Xiong, X., Sui, M., Fan, W. and Kraft, A. S. (2007) Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. Cancer Biol. Ther. 6, 1067-1073. https://doi.org/10.4161/cbt.6.7.4323
  59. Xu, K., Chen, Z., Cui, Y., Qin, C., He, Y. and Song, X. (2015) Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2/M arrest and gamma-H2AX foci formation in colorectal cancer. Onco Targets Ther. 8, 3047-3054.
  60. Yoon, H. and Ko, Y. H. (2017) LMP1+SLAMF1high cells are associated with drug resistance in Epstein-Barr virus-positive Farage cells. Oncotarget 8, 24621-24634.

Cited by

  1. YDJC Induces Epithelial-Mesenchymal Transition via Escaping from Interaction with CDC16 through Ubiquitination of PP2A vol.2019, pp.None, 2018, https://doi.org/10.1155/2019/3542537
  2. Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role vol.26, pp.None, 2019, https://doi.org/10.2174/0929867326666190712160842
  3. The impact of EBV on the epigenetics of gastric carcinoma vol.15, pp.3, 2018, https://doi.org/10.2217/fvl-2019-0148